Pelvic Floor Magnetic Stimulation in Women With Idiopathic Overactive Bladder

October 31, 2022 updated by: Necmettin Yildiz, Pamukkale University

Combined Effect of Pelvic Floor Magnetic Stimulation and Bladder Training in Women With Idiopathic Overactive Bladder: A Prospective Randomised Controlled Trial

In clinical practice, Bladder Training (BT) and Magnetic stimulation (MS) are frequently used together in the treatment of women with idiopathic overactive bladder (OAB). Up to our knowledge, there is no study evaluating the combined effect of magnetic stimulation and bladder training in women with idiopathic OAB in the literature. Moreover, there is no recommendation on conservative treatment combinations in the guidelines due to insufficient data. At this stage, studies are needed to determine whether it will be effective to use MS in combination with other conservative treatment options. In addition, in the light of our clinical experience, we think that this issue is still open for research. In our study, adding MS to BT in women with idiopathic OAB is thought to contribute additionally to the efficacy of treatment with BT.

Our study is the first prospective randomized controlled trial that compares the efficacy of BT and BT plus MS in women with idiopathic OAB. In this study, we aimed to evaluate the efficacy of MS added to BT on incontinence-related QoL and clinical parameters in women with idiopathic OAB.

Study Overview

Detailed Description

This study is a prospectively randomized, controlled trial. The trial is held at Urogynecological Rehabilitation Unit of University Hospital, Physical Medicine and Rehabilitation Department between September 2020 and November 2021. The local ethics committee approve the study (approval no: 60116787-020/37878). Patients are informed about the purpose and contents of the study and all women give written consent to participate.

By using a random number generator, all patients which included the study were randomized into two groups as follows: The Group 1 received BT program alone, the Group 2 received BT plus MS.

Group 1: Bladder Training (BT) - Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.

BT, consisting of four stages, did not contain any pelvic floor muscle (PFM) training programs in two groups.

Group 2: BT plus MS Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is inserted by this magnetic field, an eddy current flow is generated. This eddy current stimulates nerve or muscle of the pelvic floor. To apply MS, the device was set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature (10,13-15). When setting the device at each treatment session, patients were interviewed so that they received stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) (10). MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks. MS sessions were performed by other physician.

Study Type

Interventional

Enrollment (Actual)

76

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Kınıklı
      • Denizli, Kınıklı, Turkey, 20100
        • Pamukkale University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Women over the age of 18 with clinical diagnosis of idiopathic OAB
  2. Urodynamically confirmed detrusor overactivity (the presence of detrusor contractions in the filling phase of saline cystometry)
  3. Not tolerated or unresponsive to antimuscarinics and discontinued at least 4 weeks
  4. Able to give written, informed consent
  5. Able to understand the procedures, advantages and possible side effects
  6. Willing and able to complete the voiding diary and QoL questionnaire
  7. The strength of PFM 3/5 and more

Exclusion Criteria:

  1. History of BT, MS therapy
  2. Pregnancy or intention to become pregnant during the study
  3. Current vulvovaginitis or urinary tract infections or malignancy
  4. More than stage 2 according to the pelvic organ prolapse quantification
  5. Cardiac pacemaker, implanted defibrillator, coronary artery stent
  6. Ongoing treatment for arrhythmia
  7. Lower abdominal pain or dysmenorrhea yet to be diagnosed
  8. Electronic device or metallic implant applied to areas between the lumbar region and lower extremities
  9. Previous urogynecological surgery within 3 months
  10. Ongoing surgical treatment or treatment with implantable devices for urinary incontinence or use of intrauterine copper devices
  11. Neurogenic bladder, signs of neurologic abnormalities at objective examination; history of the peripheral or central neurologic pathology
  12. Ultrasonographic evidence of post voiding residual volume more than 100 ml

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group 1: Bladder Training (BT)
BT, consisting of four stages, did not contain any PFM training programs in all groups. In these stages, including urgency suppression strategies, it was aimed to delay urination, to inhibit detrusor contraction and to prevent urgency; by squeezing the PFM several times in a row (women were encouraged to pause/stop their work, sit down if possible, relax the entire body and squeeze PFM repeatedly), breathing deeply, giving their attention to another job for a while and self-motivating (I can do it, I can check the urination, etc.).
Bladder Training (BT)
Experimental: Group 2: Bladder Training+Magnetic Stimulation
Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is inserted by this magnetic field, an eddy current flow is generated. This eddy current stimulates nerve or muscle of the pelvic floor. To apply MS, the device was set to generate its maximum stimuli, with a stimulation pulse width of 200 μs and a stimulation repetition cycle of 10 Hz in accordance with the literature. When setting the device at each treatment session, patients were interviewed so that they received stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) .
Bladder Training (BT)
MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
Other Names:
  • Extracorporeal magnetic stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incontinence episodes
Time Frame: 6 weeks
Patients with a 50% or greater reduction in incontinence episodes were consider positive responders
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of incontinence
Time Frame: 6 weeks
The 24-hour pad test was carried out to evaluate urinary loss.
6 weeks
Nocturia
Time Frame: 6 weeks
It was used "nocturia" from data collected with a 3-day bladder diary.
6 weeks
Frequency
Time Frame: 6 weeks
It was used "frequency" from data collected with a 3-day bladder diary.
6 weeks
Number of pads
Time Frame: 6 weeks
It was used "number of pads" from data collected with a 3-day bladder diary.
6 weeks
Symptom severity
Time Frame: 6 weeks
Overactive Bladder Questionnaire (OAB-V8) was used to evaluate symptom severity in patients with in the study.
6 weeks
QoL
Time Frame: 6 weeks
The Incontinence Impact Questionnaire (IIQ-7) scale which has great validity in studies was used to assess the patient's QoL associated with incontinence problem
6 weeks
Sexual Functions
Time Frame: 6 weeks
The Female Sexual Function Index (FSFI) is a valid, reliable, and anonymously designed ques¬tionnaire with six areas (desire, subjective arousal, lubrica¬tion, orgasm, satisfaction, pain), and includes 19 questions that measure female sexual function.
6 weeks
Cure and improvement rate
Time Frame: 6 weeks
In 24-hour pad test, 1.3 gr under of it was considered as a cure. The improvement was assessed in terms of 50% and more reduction in wet weight compared to baseline measurements in the 24-hour pad test
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Actual)

September 30, 2021

Study Completion (Actual)

November 29, 2021

Study Registration Dates

First Submitted

June 25, 2020

First Submitted That Met QC Criteria

June 26, 2020

First Posted (Actual)

June 29, 2020

Study Record Updates

Last Update Posted (Actual)

November 1, 2022

Last Update Submitted That Met QC Criteria

October 31, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urge Incontinence Episodes After the Magnetic Stimulation Added to Bladder Training in Women With Idiopathic Overactive Bladder

Clinical Trials on Bladder Training (BT)

Subscribe